METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody combo aims to boost lung cancer treatment response
Disease control Recruiting nowThis study tests whether adding the experimental drug visugromab to standard chemotherapy and immunotherapy can shrink tumors better than placebo in people with newly diagnosed metastatic non-squamous non-small cell lung cancer. About 107 adults who have not had prior treatment f…
Matched conditions: METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated May 17, 2026 07:54 UTC
-
Cancer-Fighting virus takes on lung cancer in new trial
Disease control Recruiting nowThis study tests a new approach for people with advanced lung cancer whose disease got worse after initial treatment. It combines an injected virus (Olvi-Vec) that attacks cancer cells, followed by standard chemotherapy plus an immunotherapy drug, and compares it to standard chem…
Matched conditions: METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated May 17, 2026 07:37 UTC
-
New drug cocktail aims to shrink lung tumors in Late-Stage trial
Disease control Recruiting nowThis study tests whether adding the experimental drug visugromab to standard immunotherapy and chemotherapy can shrink tumors better than chemotherapy alone in people with advanced non-squamous lung cancer. About 131 participants who have already tried one prior treatment will re…
Matched conditions: METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated May 12, 2026 13:43 UTC